Bayer AGFRA:BAYA +24.87%62 Days Payable is 119.17 as of Mar. 2026, which is 11% below its 10-year median of 133.92. GuruFocus rates FRA:BAYA with a GF Score™ of 62/100 and a GF Value™ of €6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Bayer AG ranks better than 68.91% on this metric.
Bayer AG's average Accounts Payable for the
three
months ended in Mar. 2026 was €6,833 Mil. Bayer AG's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €5,232 Mil.
Hence, Bayer AG's Days Payable for the
three
months ended in Mar. 2026 was 119.17.
The historical rank and industry rank for Bayer AG's Days Payable or its related term are showing as below:
FRA:BAYA'
s Days Payable Range Over the Past 10 Years
Min: 115.42 Med: 133.92 Max: 191.8
Current: 129.59
During the past 13 years, Bayer AG's highest Days Payable was 191.80. The lowest was 115.42. And the median was 133.92.
FRA:BAYA's Days Payable is ranked better than 68.91% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs FRA:BAYA: 129.59
Bayer AG's Days Payable
increased
from Mar. 2025 (114.41) to Mar. 2026 (119.17).
It may suggest that Bayer AGdelayed paying its suppliers.
Bayer AG Days Payable Related Terms
Bayer AG Days Payable Historical Data
* Premium members only.
The historical data trend for Bayer AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BAYA vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Bayer AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bayer AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (FRA:BAYA) has a Days Payable of 119.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bayer AG and its competitors. This is 11% below median its historical median of 133.92. Over the past decade, Bayer AG's Days Payable has ranged from 115.42 to 191.80. According to the industry distribution chart, Bayer AG ranks #287 out of 923 companies in the Drug Manufacturers industry, placing it in the top 31.1%.
Is Bayer AG's Days Payable too high?
Bayer AG's current Days Payable of 119.17 is 11% below median its 10-year median of 133.92. Over the past 10 years, this metric has ranged from a low of 115.42 to a high of 191.80. The Drug Manufacturers industry median Days Payable is 90.98. Bayer AG's value of 119.17 is 31% above this industry median. Based on the distribution chart, Bayer AG ranks #287 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bayer AG has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #287 out of 923 companies for Days Payable. This puts Bayer AG in the upper half of its industry. The industry median Days Payable is 90.98. Bayer AG's value of 119.17 is 31% above this benchmark. Historically, Bayer AG's own Days Payable has ranged from 115.42 to 191.80 over the past decade. While the company's 10-year median is 133.92 vs. the industry median of 90.98, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current Days Payable of 119.17 is 31% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Days Payable is 119.17, which is 11% below median its own 10-year median of 133.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (FRA:BAYA) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.80, compared to a current price of €11.80 — trading 73.5% above its estimated fair value. The current Days Payable is 119.17, which is 11% below median its 10-year median of 133.92 and 31% above the Drug Manufacturers industry median of 90.98. Bayer AG's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bayer AG (FRA:BAYA), the current Days Payable is 119.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (FRA:BAYA) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of €11.80 is trading 73.5% above its estimated GF Value™ of €6.80.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for FRA:BAYA:
Days Payable: 119.17 (11% below median its 10-year median of 133.92)
GF Value™: €6.80 vs. price of €11.80 (73.5% above fair value)
Industry Position: 31% above the Drug Manufacturers median (#287 of 923)
No single metric tells the full story. See the FRA:BAYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
62GF Score
Get the complete analysis for FRA:BAYA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BAYA has been successfully added to your 
